Fellow of the Academy of Medical Sciences

Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, March 29, 2022
Administration, Company, Partnership, Therapy, TWELVE, State Administrative Expenses, Lung, Society, Growth, Clinical trial, SVB, Silicon Valley Bank, Research, Doctor of Philosophy, Standard of care, Cancer, CEO, NSCLC, PD-1, MD, RAC, CADL, Industry, Safety, Senior advisor, Brain, GLOBE, Income, Nivolumab, Valaciclovir, Development, IPO, PD-L1, Patient, Large-cell lung carcinoma, Pharmaceutical industry, Vaccine, Animal, Fellow of the Academy of Medical Sciences, Candel, Pfizer

NEEDHAM, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Key Points: 
  • NEEDHAM, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
  • 2021 was a year of significant progress for Candel, filled with important accomplishments in development of our late-stage pipeline of novel oncolytic viral immunotherapies for cancer treatment.
  • Financial Results for the Year and Fourth Quarter Ended December 31, 2021
    Cash Position: Cash and cash equivalents as of December 31, 2021 were $82.6 million, compared to $35.1 million as of December 31, 2020.
  • Subsequent to December 31, 2021, the Company entered into a term loan agreement with SVB and borrowed $20.0 million.

Invitae Launches Full Access to its Liquid-Based Personalized Cancer Monitoring Platform to Help Detect Disease Earlier

Retrieved on: 
Thursday, March 17, 2022
Francis Crick Institute, ARTEMIS, Technology, Risk, GI, University College London, Neck, CEO, U.S. Securities and Exchange Commission, Lung cancer, Liquid biopsy, Partnership, Private Securities Litigation Reform Act, Plasma, Neoplasm, Collection, Diagnosis, Forward-looking statement, Head, Clinical trial, Research, Cancer, WES, Growth, NYSE, FRCP, NGS, MRD, Recurrence, Method, Patient, Cancer Research UK, Publication, Professor, Security (finance), Cohort study, FRS, Cancer research, PCM, SAN, Disease, Annual report, Breast, University College London Hospitals NHS Foundation Trust, UCL, National Institute, Pancreatic cancer, Blood, Lung, DNA, Medical imaging, Pharmaceutical industry, Fellow of the Academy of Medical Sciences, Invitae

SAN FRANCISCO, March 17, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors. Invitae PCM uses a novel set of personalized assays based on a patient's tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification, response assessment to treatment and detection of cancer recurrence, based on recent studies. 

Key Points: 
  • SAN FRANCISCO, March 17, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors.
  • With these capabilities, MRD monitoring promises to shorten clinical trials and accelerate the development of potentially life-saving new drugs.
  • Each assay is custom designed to detect a patient's unique tumor signature, allowing for personalized results to guide treatment decisions.
  • TRACERx (TRAcking Cancer Evolution through therapy (Rx)) lung study is the single biggest investment in lung cancer research by Cancer Research UK.

Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery

Retrieved on: 
Thursday, March 10, 2022
Research, Pharmaceutical, Oncology, Technology, University, Education, Clinical Trials, Science, Biotechnology, Stem Cells, Other Technology, Health, Nasdaq, Industry, Genomics, University, Private Securities Litigation Reform Act, Drug development, Partnership, Research, FRS, Nobel Prize, Science, Patient, Portfolio management, Doctor of Philosophy, Nobel Prize in Physiology or Medicine, Biomedical Research, Nuffield Department of Population Health, Genetics, Program, CEO, Antibiotics, Pharmaceutical industry, Fellow of the Academy of Medical Sciences, Medicine

The Xcellomics program was created by the two Oxford-based institutions to expedite early-stage drug discovery research primarily conducted within academic labs and potentially leverage those outputs to bring therapies to patients sooner.

Key Points: 
  • The Xcellomics program was created by the two Oxford-based institutions to expedite early-stage drug discovery research primarily conducted within academic labs and potentially leverage those outputs to bring therapies to patients sooner.
  • The program offers applicants resources to explore, identify and rapidly advance novel drug targets by leveraging Oxford TDIs expertise in developing robust, disease-relevant, predictive screening assays and Exscientias AI personalised medicine design capabilities.
  • The Xcellomics Board provides oversight and is comprised of members from Exscientia and Oxford TDI, and is chaired by Exscientias founder and CEO, Andrew Hopkins, DPhil.
  • The centre aims to link recent advances in genetics, genomics, cell and chemical biology for improved drug target discovery.

DGAP-News: Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis

Retrieved on: 
Thursday, March 10, 2022
Maintenance, Patient, CET, Rheumatoid arthritis, Crohn's disease, Immune system, Euronext Paris, Cancer, ACR20, Ulcerative colitis, RA, Infection, Degenerative disease, Stanford University, Physiology, Division, Immunology, CEO, Health insurance, Pharmaceutical industry, G7, Fellow of the Academy of Medical Sciences, Abivax, Rheumatology

Along with its very different mode of action and clinical profile, ABX464 has the potential to play an important role in the future management of rheumatoid arthritis patients."

Key Points: 
  • Along with its very different mode of action and clinical profile, ABX464 has the potential to play an important role in the future management of rheumatoid arthritis patients."
  • Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: "These results clearly support the continued clinical development of ABX464 for the treatment of RA.
  • 58% of the patients (23/40) suffering from moderate to severe active RA completed 52 weeks of chronic treatment with ABX464.
  • Efficacy of 50mg once daily ABX464 was assessed by the DAS28-CRP remission (DAS28-CRP

Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer

Retrieved on: 
Wednesday, March 2, 2022
Private Securities Litigation Reform Act, BLA, Purdue University, Patient, Â, Research, Virus, Biological engineering, Tisagenlecleucel, Roche, ImClone Systems, Eli Lilly, MS, Merck, Character, FDA, Church Avenue station (IND Culver Line), CGT, RAC, Rutgers University, Therapy, Late, SEC, Company, Joint Planning and Development Office, Cancer, Form, Immunogenic cell death, CEO, Biochemistry, HSV, Content discovery platform, Technology, Fellow of the Academy of Medical Sciences, CADL, Nasdaq, GLOBE, Pharmaceutical industry, Doctor of Philosophy, Biogen, Candel, Novartis

NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Seshu Tyagarajan Ph.D., RAC, has been named as the companys Chief Technical and Development Officer.

Key Points: 
  • NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Seshu Tyagarajan Ph.D., RAC, has been named as the companys Chief Technical and Development Officer.
  • Dr. Tyagarajan brings to Candel over two decades of technical, manufacturing and development experience in biologics and cell and gene therapies (CGT).
  • Dr. Tyagarajan joins the company from Novartis, where she was most recently Executive Director and Global Head, Late Stage CMC Strategy for CGT.
  • Dr. Tyagarajan holds a Ph.D. in Chemical and Biochemical Engineering from Rutgers University and an MS in Bioengineering from Purdue University.

Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Virus, Immunogenic cell death, Content discovery platform, Fellow of the Academy of Medical Sciences, Therapy, Company, Clinical trial, Private Securities Litigation Reform Act, Form, HSV, CADL, Cancer, Silicon Valley Bank, Nasdaq, Patient, Technology, Large-cell lung carcinoma, MD, Doctor of Philosophy, SEC, Pharmaceutical industry, Candel

NEEDHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (the Company or Candel), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that it has entered into a loan and security agreement with Silicon Valley Bank for $25 million, $20 million of which will be available immediately.

Key Points: 
  • NEEDHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (the Company or Candel), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that it has entered into a loan and security agreement with Silicon Valley Bank for $25 million, $20 million of which will be available immediately.
  • An additional $5 million may be made available in the future if certain conditions and milestones are met.
  • The loan agreement requires monthly payments of interest only for 24 months, after which the principal is repayable in 24 monthly payments.
  • This financing extends the Companys cash runway into the fourth quarter of 2023.

DnaNudge Launch 90-Minute RT-PCR Covid-19 Test in Australia

Retrieved on: 
Wednesday, February 16, 2022
Infectious Diseases, Health, Medical Supplies, Cloud, Pantonality, RSV, CEO, DnaNudge, COVID, Type 2 diabetes, COVID-19, Royal, Cholesterol, Eating, PCR, RT, Technology, Omicron, Virus, Infection, RT-PCR, Diabetes, Hypertension, Partnership, Hospital, Ageing, Prison, Mining, Pathology, Laboratory information management system, DNA, TGA, FRS, Obesity, Industry, Whiddon, Medical imaging, Pharmaceutical industry, Medical device, NSW, Fellow of the Academy of Medical Sciences

CEO and co-founder of DnaNudge, Regius (Royal) Professor Chris Toumazou FRS, FREng, FMedSci, said: We are delighted to launch our technology in Australia through our partnership with Pantonic Health.

Key Points: 
  • CEO and co-founder of DnaNudge, Regius (Royal) Professor Chris Toumazou FRS, FREng, FMedSci, said: We are delighted to launch our technology in Australia through our partnership with Pantonic Health.
  • We hope that by making our rapid, lab-free RT-PCR test more widely available, will offer further support to Australias Covid response.
  • Chris Mamarelis, CEO of Whiddon Aged Care, described the DnaNudge technology as a game changer to the currently capacity constrained Covid testing landscape in Australia.
  • We believe it should be deployed for every aged care facility and hospital across Australia as a matter of urgency.

Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer

Retrieved on: 
Thursday, February 3, 2022
Fellow of the Academy of Medical Sciences, Leadership, CEO, Private Securities Litigation Reform Act, Patient, CADL, Therapy, Immune system, University, SEC, University of Birmingham, Form, Flagship Pioneering, Technology, Cancer, American University of Rome, Kintai, HSV, Immunogenic cell death, Company, Medical research, GLOBE, Content discovery platform, Industry, Virus, Reader, Associate, Nasdaq, Vaccine, Candel

NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Francesca Barone, M.D., Ph.D., has been named as the companys Chief Scientific Officer.

Key Points: 
  • NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Francesca Barone, M.D., Ph.D., has been named as the companys Chief Scientific Officer.
  • Prior to Candel, Dr. Barone was Head of Experimental Medicine at Kintai Therapeutics and Senda Biosciences, two Flagship Pioneering companies.
  • Before moving to industry, Dr. Barone was a Rheumatology Consultant and Associate Professor (Reader) at University of Birmingham.
  • I look forward to her continued leadership as we advance Candel Therapeutics investigational immunotherapies in clinical development, supported by cutting-edge immunological research.

Candel Therapeutics to Present at Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, January 5, 2022
Therapy, Content discovery platform, Doctor of Philosophy, Company, Form, Patient, Cancer, Immunogenic cell death, Private Securities Litigation Reform Act, HSV, MD, SEC, Virus, GLOBE, Technology, Nasdaq, CADL, Online shopping, Vaccine, Fellow of the Academy of Medical Sciences, Candel

CAN-2409 is the lead product candidatefrom the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.

Key Points: 
  • CAN-2409 is the lead product candidatefrom the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • TheenLIGHTEN Discovery Platform is based onCandelsHSV technology.
  • For more information about Candel, visit www.candeltx.com .
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies

Retrieved on: 
Wednesday, December 15, 2021
Method, Therapy, Hope, Company, Brain, Therapeutic index, Doctor of Philosophy, Toxicity, Max Planck Society, CNS, Organic acid, Nasdaq, Private Securities Litigation Reform Act, Cancer, SEC, CEO, Research, Safety, Patient, Disease, HSV, Neoplasm, Engineering, Immunogenic cell death, MD, Virus, Potyvirus, GLOBE, CADL, Content discovery platform, Mouse, Technology, Max Planck Institute for Experimental Medicine, Pharmaceutical industry, Medical imaging, Medical device, Vaccine, Candel, Fellow of the Academy of Medical Sciences

Bionaut Labs is excited to partner with Candel, a leader in developing oncolytic viruses for multiple cancers, to advance much-needed treatment options for brain cancer patients leveraging our transformative Bionaut platform technology," said Michael Shpigelmacher, co-founder and CEO, Bionaut Labs.

Key Points: 
  • Bionaut Labs is excited to partner with Candel, a leader in developing oncolytic viruses for multiple cancers, to advance much-needed treatment options for brain cancer patients leveraging our transformative Bionaut platform technology," said Michael Shpigelmacher, co-founder and CEO, Bionaut Labs.
  • Through precise targeting, Bionaut therapeutics could offer better efficacy and safety that cannot be achieved by other traditional treatment or delivery modalities.
  • Candel is a late clinical-stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies.
  • Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.